MW-189 is under clinical development by ImmunoChem Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MW-189’s likelihood of approval (LoA) and phase transition for Hemorrhagic Shock took place on 03 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MW-189 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MW-189 overview

MW-189 is under development for the treatment of for the treatment of Alzheimer's disease (AD), aneurysmal subarachnoid hemorrhage, rheumatoid arthritis (RA), intracerebral hemorrhage (ICH), traumatic brain injury (TBI) and neuropathic pain. The drug candidate is administered by intravenous injection or orally. The drug candidate acts by targeting the overproduction of inflammatory cytokines, such as interleukin-1 (IL-1beta), tumour necrosis factor-alpha (TNF-alpha).

Quick View MW-189 LOA Data

Report Segments
  • Innovator
Drug Name
  • MW-189
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Immunology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.